CStone Pharmaceuticals (HKG:2616)
Hong Kong · Delayed Price · Currency is HKD 5.90
+0.34 (6.12%)
Sep 30, 2026, 4:08 PM HKT
CStone Pharmaceuticals Market Cap
CStone Pharmaceuticals has a market cap or net worth of 9.39 billion as of September 29, 2026. Its market cap has decreased by -16.99% in one year.
Market Cap
9.39B
Enterprise Value
7.93B
Revenue
490.92M
Ranking
n/a
PE Ratio
n/a
Stock Price
5.90
ChartMarket Cap Chart
Since February 26, 2019, CStone Pharmaceuticals's market cap has decreased from 12.65B to 9.39B, a decrease of -25.79%. That is a compound annual growth rate of -3.85%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 30, 2026 | 9.39B | 20.89% |
| Dec 31, 2025 | 7.77B | 164.57% |
| Dec 31, 2024 | 2.94B | 1.52% |
| Dec 29, 2023 | 2.89B | -47.58% |
| Dec 30, 2022 | 5.52B | -42.71% |
| Dec 31, 2021 | 9.63B | -16.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Feb 26, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| GenFleet Therapeutics (Shanghai) | 12.22B |
| HBM Holdings | 11.44B |
| Ascentage Pharma Group International | 11.31B |
| Everest Medicines | 10.60B |
| Nanjing Leads Biolabs | 9.83B |
| Suzhou Ribo Life Science | 9.27B |
| Ascletis Pharma | 8.77B |
| Alphamab Oncology | 7.80B |